Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 22Gastrointestinal 14Breast 13Thoracic 12Head & Neck 10Gynecologic 10Dermatologic 9Sarcoma 5CNS 3Plasma cell 1Other neoplasm 1NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Neuroendocrine Tumors 111Gastro-enteropancreatic neuroendocrine tumor 19Carcinoma, Neuroendocrine 12Stomach Neoplasms 11Pancreatic Neoplasms 10Neoplasms 10Breast Neoplasms 10Pheochromocytoma 9Carcinoid Tumor 9Prostatic Neoplasms 8Paraganglioma 8Neoplasm Metastasis 8Carcinoma, Hepatocellular 8Adenoma, Islet Cell 8Thyroid Neoplasms 7Sarcoma 7Gastrointestinal Neoplasms 7Esophageal Neoplasms 7Colorectal Neoplasms 7Lung Neoplasms 6Rectal Neoplasms 5Ovarian Neoplasms 5Neuroblastoma 5Melanoma 5Liver Neoplasms 5Colonic Neoplasms 5Anus Neoplasms 5Uterine Cervical Neoplasms 4Gastrointestinal Stromal Tumors 4Cholangiocarcinoma 4

Interventions

pembrolizumab 1fludarabine 1aldesleukin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Urogenital Neoplasms × NET × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡